according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Spiramycin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
1.11	06.04.2024	7979094-00012	Date of first issue: 19.03.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier		
	Trade name	:	Spiramycin Formulation
1.2	Relevant identified uses of the	ne s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Veterinary product
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD
			Kilsheelan
			Clonmel Tipperary, IE
	Telephone	:	353-51-601000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Eye irritation, Category 2	
Reproductive toxicity, Category 1B	

H319: Causes serious eye irritation. H360FD: May damage fertility. May damage the unborn child.

2.2 Label elements

Signal word

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Hazard statements



H360FD

Causes serious eye irritation. May damage fertility. May damage the unborn

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Spiramycin Formulation

Version 1.11	Revision Date: 06.04.2024	SDS Number: 7979094-0001	
			child.
Preca	autionary statements	: Preventior	::
		P201	Obtain special instructions before use.
		P264	Wash skin thoroughly after handling.
		P280	Wear protective gloves/ protective clothing/ eye protection/ face protection.
		Response	
		P308 + P31	13 IF exposed or concerned: Get medical advice/ attention.
		P337 + P31	I3 If eye irritation persists: Get medical advice/ attention.
		Storage:	
		P405	Store locked up.

Hazardous components which must be listed on the label:

2-Pyrrolidone

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

oompononto			
Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
2-Pyrrolidone	616-45-5 210-483-1	Eye Irrit. 2; H319 Repr. 1B; H360FD specific concentration limit Repr. 1B; H360FD > 3 %	>= 30 - < 50
Benzyl alcohol	100-51-6	Acute Tox. 4; H302	>= 1 - < 10



according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Spiramycin Formulation

ersion Revision Date: .11 06.04.2024		SDS Number: 7979094-00012	Date of last issue: 30.09.2023 Date of first issue: 19.03.2021			
		202-859-9 603-057-00-5	Acute Tox. 4; H332 Eye Irrit. 2; H319 Acute toxicity esti- mate Acute oral toxicity: 1,620 mg/kg			
Spira	mycin	8025-81-8 232-429-6	< 0.1			

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
4.2 Most important symptoms ar	nd e	effects, both acute and delayed
Risks	:	Causes serious eye irritation. May damage fertility. May damage the unborn child.
4.3 Indication of any immediate r	me	dical attention and special treatment needed
Treatment	:	Treat symptomatically and supportively.
3 / 21		

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Spiramycin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
1.11	06.04.2024	7979094-00012	Date of first issue: 19.03.2021

SECTION 5: Firefighting measures

5.1	Extinguishing media		
	Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
	Unsuitable extinguishing media	:	None known.
5.2	Special hazards arising from	the	e substance or mixture
	Specific hazards during fire- fighting	:	Exposure to combustion products may be a hazard to health.
	Hazardous combustion prod- ucts	:	Nitrogen oxides (NOx) Carbon oxides
5.3	Advice for firefighters		
	Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
	Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Spiramycin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
1.11	06.04.2024	7979094-00012	Date of first issue: 19.03.2021
		ment to keep m be pumped, sto Clean up remain bent. Local or nationa posal of this ma employed in the mine which regu Sections 13 and	provide dyking or other appropriate contain- aterial from spreading. If dyked material can re recovered material in appropriate container. ning materials from spill with suitable absor- al regulations may apply to releases and dis- terial, as well as those materials and items e cleanup of releases. You will need to deter- ulations are applicable. d 15 of this SDS provide information regarding national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

	5	
Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing. Do not breathe vapours or spray mist. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Keep container tightly closed. Take care to prevent spills, waste and minimize release to the
Hygiene measures	:	environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
7.2 Conditions for safe storage	e, inc	luding any incompatibilities
Requirements for storage areas and containers	:	Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage	:	Do not store with the following product types: Strong oxidizing agents
		Self-reactive substances and mixtures
		Organic peroxides

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Spiramycin Formulation

Version 1.11	Revision Date: 06.04.2024	SDS Number: 7979094-00012	Date of last issue: 30.09.2023 Date of first issue: 19.03.2021
		Explosives Gases	
-	c end use(s) ic use(s)	: No data available	e

SECTION 8: Exposure controls/personal protection


8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Spiramycin	8025-81-8	TWA	1000 ug/m3 (OEB 1)	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
2-Pyrrolidone	Workers	Inhalation	Long-term systemic effects	57.8 mg/m3
	Workers	Skin contact	Long-term systemic effects	10 mg/kg bw/day
	Workers	Skin contact	Acute systemic ef- fects	277 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	17.1 mg/m3
	Consumers	Skin contact	Long-term systemic effects	6 mg/kg bw/day
	Consumers	Skin contact	Acute systemic ef- fects	167 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	5.2 mg/kg bw/day
	Consumers	Ingestion	Acute systemic ef- fects	33.3 mg/kg bw/day
Benzyl alcohol	Workers	Inhalation	Long-term systemic effects	22 mg/m3
	Workers	Inhalation	Acute systemic ef- fects	110 mg/m3
	Workers	Skin contact	Long-term systemic effects	8 mg/kg bw/day
	Workers	Skin contact	Acute systemic ef- fects	40 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	5.4 mg/m3
	Consumers	Inhalation	Acute systemic ef- fects	27 mg/m3
	Consumers	Skin contact	Long-term systemic effects	4 mg/kg bw/day
	Consumers	Skin contact	Acute systemic ef-	20 mg/kg





Spiramycin Formulation

	Date of last issue: 30.09.2023 Date of first issue: 19.03.2021
--	---

		fects	bw/day
Consumers	Ingestion	Long-term systemic	4 mg/kg
		effects	bw/day
Consumers	Ingestion	Acute systemic ef-	20 mg/kg
		fects	bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
2-Pyrrolidone	Fresh water	0.5 mg/l
	Freshwater - intermittent	0.5 mg/l
	Marine water	0.05 mg/l
	Sewage treatment plant	10 mg/l
	Fresh water sediment	0.4205 mg/kg dry
		weight (d.w.)
	Soil	0.0612 mg/kg dry
		weight (d.w.)
Benzyl alcohol	Fresh water	1 mg/l
	Marine water	0.1 mg/l
	Intermittent use/release	2.3 mg/l
	Sewage treatment plant	39 mg/l
	Fresh water sediment	5.27 mg/kg
	Marine sediment	0.527 mg/kg
	Soil	0.456 mg/kg

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

Personal protective equipment				
Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.		
Hand protection Material	:	Chemical-resistant gloves		
Skin and body protection Respiratory protection	:	Work uniform or laboratory coat. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387		
Filter type	:	Organic vapour type (A)		

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Versior 1.11	n	Revision Date: 06.04.2024		S Number: 9094-00012	Date of last issue: 30.09.2023 Date of first issue: 19.03.2021
Pł	hysica	l state	:	Aqueous solution	
Co	olour		:	light yellow	
0	dour		:	No data available	
0	dour T	hreshold	:	No data available	
M	lelting	point/freezing point	:	No data available	•
	itial bo inge	iling point and boiling	:	No data available	
Fl	lamma	bility (solid, gas)	:	Not applicable	
Fl	lamma	bility (liquids)	:	No data available	
		xplosion limit / Upper pility limit	:	No data available	
		xplosion limit / Lower pility limit	:	No data available	
Fl	lash po	pint	:	No data available	
Au	uto-igr	nition temperature	:	No data available	
De	ecomp	oosition temperature	:	No data available	
pł	Η		:	8.0 - 10.0	
Vi	iscosit Visco	y osity, kinematic	:	No data available	
So	olubilit Wate	y(ies) er solubility	:	No data available	
	artitior ctanol/	o coefficient: n- water	:	Not applicable	
Va	apour	pressure	:	No data available	
Re	elative	density	:	No data available	
De	ensity		:	0.950 - 1.150 g/ci	m ³
Re	elative	vapour density	:	No data available	
Pa		characteristics cle size	:	Not applicable	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Spiramycin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023	
1.11	06.04.2024	7979094-00012	Date of first issue: 19.03.2021	

9.2 Other information

Explosives	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Evaporation rate	:	No data available
Molecular weight	:	No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes Information on likely routes of : exposure	as defined in Regulation (EC) No 1272/2008 Inhalation Skin contact Ingestion Eye contact
Acute toxicity Not classified based on available	information.
Product:	
Acute oral toxicity :	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
Acute inhalation toxicity :	Acute toxicity estimate: > 5 mg/l Exposure time: 4 h Test atmosphere: dust/mist

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



rsion 1	Revision Date: 06.04.2024		DS Number:Date of last issue: 30.09.202379094-00012Date of first issue: 19.03.2021
			Method: Calculation method
<u>Comp</u>	oonents:		
2-Pyr	rolidone:		
-	oral toxicity	:	LD50 (Rat): > 2,000 mg/kg Method: OECD Test Guideline 401 Assessment: The substance or mixture has no acute oral to icity
Acute	dermal toxicity	:	LD50 (Rabbit): > 2,000 mg/kg Method: OECD Test Guideline 402 Assessment: The substance or mixture has no acute derma toxicity
-	/l alcohol:		
Acute	oral toxicity	:	LD50 (Rat): 1,620 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): > 4.178 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: OECD Test Guideline 403
Spira	mycin:		
Acute	oral toxicity	:	LD50 (Mouse, adult): 2,900 mg/kg
			LD50 (Rat, adult): 3,550 mg/kg
			LD50 (Dog, adult): 5,200 mg/kg
			LD50 (Rabbit, adult): 4,300 mg/kg
Acute	inhalation toxicity	:	Remarks: No data available
	toxicity (other routes of istration)	:	LD50 (Mouse): 130 mg/kg Application Route: Intravenous
			LD50 (Rat): 170 mg/kg Application Route: Intravenous
			LD50 (Rabbit): 182 mg/kg Application Route: Intravenous
Skin d	corrosion/irritation		
Not cl	assified based on availa	ble	information.
Comp	oonents:		
2	rolidone:		
Specie Metho		:	Rabbit OECD Test Guideline 404

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



ersion 11	Revision Date: 06.04.2024		OS Number: 79094-00012	Date of last issue: 30.09.2023 Date of first issue: 19.03.2021	
Resul	t	:	No skin irritatior		
Benzy	yl alcohol:				
Speci	es	:	Rabbit		
Metho	bd	:	OECD Test Gui		
Resul	t	:	No skin irritatior		
Serio	us eye damage/eye	irritati	on		
Cause	es serious eye irritatio	on.			
<u>Comp</u>	oonents:				
2-Pyr	rolidone:				
Speci		:	Rabbit		
Resul	t	:	Irritation to eyes	, reversing within 7 days	
Benzy	yl alcohol:				
Speci		:	Rabbit		
Metho		:	OECD Test Gui		
Resul	t	:	Irritation to eyes	, reversing within 21 days	
			-		
Resp	iratory or skin sensi	itisatio	n		
-	-	itisatio	n		
Skin s	sensitisation				
Skin s Not cl	sensitisation assified based on ava	ailable			
Skin s Not cl Respi	sensitisation assified based on ava iratory sensitisation	ailable 1	information.		
Skin s Not cl Respi	sensitisation assified based on ava	ailable 1	information.		
Skin s Not cl Respi Not cl	sensitisation assified based on ava iratory sensitisation	ailable 1	information.		
Skin s Not cl Respi Not cl <u>Com</u>	sensitisation assified based on avain iratory sensitisation assified based on avain	ailable 1	information.		
Skin s Not cl Respi Not cl <u>Comp</u> 2-Pyr	sensitisation assified based on avaint iratory sensitisation assified based on avaint conents: rolidone:	ailable 1	information.	de assay (LLNA)	
Skin s Not cl Respi Not cl <u>Comp</u> 2-Pyr Test 1	sensitisation assified based on avaint iratory sensitisation assified based on avaint conents: rolidone:	ailable 1	information.	de assay (LLNA)	
Skin s Not cl Respi Not cl <u>Comp</u> 2-Pyr Test T Expos Speci	sensitisation assified based on avaint iratory sensitisation assified based on avaint conents: rolidone: Type sure routes es	ailable 1	information. information. Local lymph noo Skin contact Mouse		
Skin s Not cl Respi Not cl <u>Comp</u> 2-Pyr Test T Expos Speci Metho	sensitisation assified based on avaination assified based on avaination as	ailable 1	information. information. Local lymph noo Skin contact Mouse OECD Test Gui		
Skin s Not cl Respi Not cl <u>Comp</u> 2-Pyr Test T Expos Speci Metho Resul	sensitisation assified based on avainatory sensitisation assified based on avaination assified based on avaination conents: rolidone: rolidone: rype sure routes es bd t	ailable 1	information. information. Local lymph noo Skin contact Mouse OECD Test Gui negative	deline 429	
Skin s Not cl Respi Not cl <u>Comp</u> 2-Pyr Test T Expos Speci Metho	sensitisation assified based on avainatory sensitisation assified based on avaination assified based on avaination conents: rolidone: rolidone: rype sure routes es bd t	ailable 1	information. information. Local lymph noo Skin contact Mouse OECD Test Gui negative		
Skin s Not cl Respi Not cl Comp 2-Pyr Test T Expos Speci Metho Resul Rema	sensitisation assified based on avainatory sensitisation assified based on avaination assified based on avaination conents: rolidone: rolidone: rype sure routes es bd t	ailable 1	information. information. Local lymph noo Skin contact Mouse OECD Test Gui negative	deline 429	
Skin s Not cl Respi Not cl Comp 2-Pyr Test T Expos Speci Metho Resul Rema Benzy Test T	sensitisation assified based on avaination assified based on avaination as	ailable 1	information. information. Local lymph noo Skin contact Mouse OECD Test Gui negative	deline 429 rom similar materials	
Skin s Not cl Respi Not cl Comp 2-Pyr Test 1 Expos Speci Metho Resul Rema Benzy Test 1 Expos	sensitisation assified based on avaination assified based on avaination assignments assified based on avaination assignments assified based on avaination assignments assified based on avaination assified based on avaination assignments assignme	ailable 1	information. information. Local lymph nod Skin contact Mouse OECD Test Gui negative Based on data f Maximisation Te Skin contact	deline 429 rom similar materials	
Skin s Not cl Respi Not cl Comp 2-Pyr Test T Expos Speci Metho Resul Rema Benzy Test T Expos Speci	sensitisation assified based on avaination assified based on avaination assignments assified based on avaination assignments assified based on avaination assignments assified based on avaination assignments assignments assignments assified based on avaination assignments	ailable 1	information. information. Local lymph nod Skin contact Mouse OECD Test Gui negative Based on data f Maximisation Te Skin contact Guinea pig	deline 429 rom similar materials	
Skin s Not cl Respi Not cl Comp 2-Pyr Test T Expos Speci Metho Resul Rema Benzy Test T Expos Speci Metho	sensitisation assified based on avaination assified based on avaination assignments assign	ailable 1	information. information. Local lymph noo Skin contact Mouse OECD Test Gui negative Based on data f Maximisation Te Skin contact Guinea pig OECD Test Gui	deline 429 rom similar materials	
Skin s Not cl Respi Not cl Comp 2-Pyr Test T Expos Speci Metho Resul Rema Benzy Test T Expos Speci	sensitisation assified based on avaination assified based on avaination assignments assign	ailable 1	information. information. Local lymph nod Skin contact Mouse OECD Test Gui negative Based on data f Maximisation Te Skin contact Guinea pig	deline 429 rom similar materials	
Skin s Not cl Respi Not cl Comp 2-Pyr Test T Expos Speci Metho Resul Rema Benzy Test T Expos Speci Metho Resul	sensitisation assified based on avaination assified based on avaination assignments assign	ailable 1	information. information. Local lymph noo Skin contact Mouse OECD Test Gui negative Based on data f Maximisation Te Skin contact Guinea pig OECD Test Gui	deline 429 rom similar materials	
Skin s Not cl Respi Not cl Comp 2-Pyr Test T Expos Speci Metho Resul Rema Benzy Test T Expos Speci Metho Resul Rema	sensitisation assified based on avaination assified based on avaination assignments assign	ailable 1	information. information. Local lymph noo Skin contact Mouse OECD Test Gui negative Based on data f Maximisation Te Skin contact Guinea pig OECD Test Gui negative	deline 429 rom similar materials est deline 406	
Skin s Not cl Respi Not cl Comp 2-Pyr Test T Expos Speci Metho Resul Rema Benzy Test T Expos Speci Metho Resul Rema Speci Metho Resul Test T	sensitisation assified based on avaination assified based on avaination assignments assign	ailable 1	information. information. Local lymph noo Skin contact Mouse OECD Test Gui negative Based on data f Maximisation Te Skin contact Guinea pig OECD Test Gui	deline 429 rom similar materials est deline 406	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



/ersion 1.11	Revision Date: 06.04.2024	SDS Number: 7979094-00012	Date of last issue: 30.09.2023 Date of first issue: 19.03.2021
Resul	t	: Not a skin ser	nsitizer.
	cell mutagenicity assified based on ava	ailable information.	
<u>Comp</u>	oonents:		
-	rolidone: toxicity in vitro	: Test Type: Ba Result: negati	acterial reverse mutation assay (AMES)
		Method: OEC Result: negat	vitro mammalian cell gene mutation test D Test Guideline 476 ive
		Remarks: Bas	sed on data from similar materials
			nromosome aberration test in vitro D Test Guideline 473 ive
Geno	toxicity in vivo	cytogenetic as Species: Mou Application R	se oute: Intraperitoneal injection D Test Guideline 474
Benzy	yl alcohol:		
Geno	toxicity in vitro	: Test Type: Ba Result: negat	acterial reverse mutation assay (AMES)
Geno	toxicity in vivo	cytogenetic as Species: Mou	se
		Application Result: negat	oute: Intraperitoneal injection ive
Spira	mycin:		
Geno	toxicity in vitro		vitro mammalian cell gene mutation test Chinese hamster ovary cells ive
			rtogenetic assay Chinese hamster ovary cells ive
		Test Type: In Test system: Result: negat	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



1	Revision Date: 06.04.2024	SDS Number: 7979094-00012	Date of last issue: 30.09.2023 Date of first issue: 19.03.2021
Carci	nogenicity		
Not cl	lassified based on avai	able information.	
<u>Com</u>	oonents:		
2-Pyr	rolidone:		
	cation Route sure time It	: Mouse : Ingestion : 18 month(s) : negative : Based on data t	from similar materials
Benz	yl alcohol:		
	cation Route sure time od	: Mouse : Ingestion : 103 weeks : OECD Test Gui : negative	deline 451
Spira	mycin:		
	cation Route sure time	: Rat, male and f : Oral : 2 Years : negative	emale
•	oductive toxicity		
-	damage fertility. May da ponents:	amage the unborn chil	d.
Com	ponents:	amage the unborn chil	d.
<u>Com</u> r 2-Pyr		: Test Type: One Species: Rat Application Rou Result: positive	-generation reproduction toxicity study
<u>Com</u> 2-Pyr Effect	ponents: rolidone:	: Test Type: One Species: Rat Application Rou Result: positive Remarks: Base	-generation reproduction toxicity study ite: Ingestion d on data from similar materials pryo-foetal development ite: Ingestion
Com 2-Pyr Effect Effect ment	ponents: rrolidone: ts on fertility ts on foetal develop- oductive toxicity - As-	 Test Type: One Species: Rat Application Rou Result: positive Remarks: Base Test Type: Emb Species: Rat Application Rou Result: positive Clear evidence ity, based on ar 	-generation reproduction toxicity study ite: Ingestion d on data from similar materials pryo-foetal development ite: Ingestion
Comp 2-Pyr Effect Effect ment Repro	ponents: rrolidone: ts on fertility ts on foetal develop- oductive toxicity - As-	 Test Type: One Species: Rat Application Rou Result: positive Remarks: Base Test Type: Emb Species: Rat Application Rou Result: positive Clear evidence ity, based on ar 	-generation reproduction toxicity study ite: Ingestion d on data from similar materials pryo-foetal development ite: Ingestion of adverse effects on sexual function and fer imal experiments., Clear evidence of adverse

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Spiramycin Formulation

Version 1.11	Revision Date: 06.04.2024		DS Number: 79094-00012	Date of last issue: 30.09.2023 Date of first issue: 19.03.2021
			Remarks: Based	on data from similar materials
Effects ment	s on foetal develop-	:	Test Type: Embry Species: Mouse Application Route Result: negative	vo-foetal development
Spiran	nycin:			
Effects	s on fertility	:		e eproductive organs in sperm morphology, Effects on male re-
Effects ment	s on foetal develop-	:	Species: Rabbit Application Route General Toxicity Developmental To	vo-foetal development e: Oral Maternal: 100 mg/kg body weight oxicity: LOAEL: 200 mg/kg body weight kicity: LOAEL: 200 mg/kg body weight

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

2-Pyrrolidone:

Species NOAEL Application Route Exposure time Method	:	Rat 207 mg/kg Ingestion 3 Months OECD Test Guideline 408
Benzyl alcohol:		
Species NOAEL Application Route Exposure time Method		Rat 1.072 mg/l inhalation (dust/mist/fume) 28 Days OECD Test Guideline 412
Spiramycin: Species NOAEL Application Route Exposure time Target Organs		Rat, male and female 140 mg/kg Oral 13 Weeks Immune system

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 1.11	Revision Date: 06.04.2024	SDS Number:Date of last issue: 30.09.20237979094-00012Date of first issue: 19.03.2021
Expo		 Rat, male and female 5.6 mg/kg Intravenous 32 d Central nervous system
Expo		 Dog, male and female 75 mg/kg Oral 2 yr Kidney, male reproductive organs, optic nerve
Expo Numb		 Dog, male and female 169 mg/kg Intravenous 4 Weeks 2 injections per day spleen, Kidney
Expo		 Dog, male and female 50 mg/kg Intravenous 4 Weeks Central nervous system
Not c	ration toxicity lassified based on ava mation on other haz	
Endo	ocrine disrupting pro	perties
Prod		
	ssment	: The substance/mixture does not contain components consid- ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
Expe	rience with human e	xposure
Com	ponents:	
Spira	imycin:	
-	ral Information	: May cause Symptoms: Nausea, Vomiting, Diarrhoea
Furth	ner information	
Com	ponents:	
Spira	imycin:	
·	-	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 1.11	Revision Date: 06.04.2024	-	98 Number: 79094-00012	Date of last issue: 30.09.2023 Date of first issue: 19.03.2021
Rema	Remarks		No data available	
SECTION	I 12: Ecological infor	ma	tion	
12.1 Toxic	city			
Comp	oonents:			
2-Pyr	rolidone:			
Toxic	ity to fish	:	LC50 (Danio rerio Exposure time: 96 Method: OECD To	
	ity to daphnia and other ic invertebrates	:	EC50 (Daphnia m Exposure time: 48	agna (Water flea)): > 500 mg/l 3 h
Toxic plants	ity to algae/aquatic	:	ErC50 (Desmodes Exposure time: 72	smus subspicatus (green algae)): > 500 mg/l 2 h
			EC10 (Desmodes Exposure time: 72	mus subspicatus (green algae)): 22.2 mg/l 2 h
Toxic	ity to microorganisms	:	EC50 : > 1,000 m Exposure time: 30 Method: OECD Te) min
Benz	yl alcohol:			
	ity to fish	:	LC50 (Pimephales Exposure time: 96	s promelas (fathead minnow)): 460 mg/l 5 h
	ity to daphnia and other ic invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
Toxic plants	ity to algae/aquatic	:	EC50 (Pseudokiro mg/l Exposure time: 72 Method: OECD To	
			NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te	
	ity to daphnia and other ic invertebrates (Chron- icity)	:	NOEC: 51 mg/l Exposure time: 21 Species: Daphnia Method: OECD Te	magna (Water flea)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Spiramycin Formulation

Version 1.11	Revision Date: 06.04.2024		DS Number: 979094-00012	Date of last issue: 30.09.2023 Date of first issue: 19.03.2021	
12.2 Pers	12.2 Persistence and degradability				
Com	ponents:				
2-Pyr	rolidone:				
Biode	egradability	:	Result: Readily b Remarks: Based	iodegradable. on data from similar materials	
Benz	yl alcohol:				
Biode	egradability	:	Result: Readily b Biodegradation: Exposure time: 1	92 - 96 %	
12.3 Bioa	ccumulative potential				
Com	ponents:				
2-Pyr	rolidone:				
	ion coefficient: n- ol/water	:	log Pow: -0.71 Method: OECD T	est Guideline 107	
Benz	yl alcohol:				
	ion coefficient: n- ol/water	:	log Pow: 1.05		
	l ity in soil ata available				
12.5 Results of PBT and vPvB assessment					
Prod	uct:				
Asse	ssment	:	to be either persi	nixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of	
12.6 Endocrine disrupting properties					
Prod	uct:				
Asse	ssment	:	ered to have end REACH Article 5	ixture does not contain components consid- ocrine disrupting properties according to 7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.	

12.7 Other adverse effects

No data available



Commission Regulation (EU) 2020/878

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
1.11	06.04.2024	7979094-00012	Date of first issue: 19.03.2021

SECTION 13: Disposal considerations

13.1 Waste treatment methods	
Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.3 Transport hazard class(es)		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.4 Packing group		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Spiramycin Formulation

Version 1.11	Revision Date: 06.04.2024	SDS Number: 7979094-00012	Date of last issue: 30.09.2023 Date of first issue: 19.03.2021
	Cargo) Passenger)	: Not regulated as : Not regulated as	s a dangerous good s a dangerous good
14.5 Environmental hazards Not regulated as a dangerous		C C	
14.6 Special precautions for user Not applicable			
14.7 Maritime transport in bulk according to IMO instruments Remarks : Not applicable for product as supplied.			
Roma			

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mix-ture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)		Conditions of restriction for the fol- lowing entries should be considered: Number on list 3	
		Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the condi- tions in corresponding Regulation to determine whether an entry is appli- cable to the placing on the market or not.	
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable	
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	:	Not applicable	
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable	
Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable	
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable	
Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.			

Not applicable

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Spiramycin Formulation

Version 1.11	Revision Date: 06.04.2024	SDS Number: 7979094-00012	Date of last issue: 30.09.2023 Date of first issue: 19.03.2021	
The c AICS	• •	roduct are reported : not determined	d in the following inventories: ed	
DSL		: not determine	ed	
IECS	С	: not determine	ed	
15.2 Chemical safety assessment				

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Repr.

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements		
H302	:	Harmful if swallowed.
H319	:	Causes serious eye irritation.
H332	:	Harmful if inhaled.
H360FD	:	May damage fertility. May damage the unborn child.
Full text of other abbreviati	ions	
Acute Tox.	:	Acute toxicity

Acute Tox.	: Acute toxicity
Eve Irrit.	: Eve irritation

•	Lyennauon
:	Reproductive toxicity

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quanti-



Spiramycin Formulation

Commission Regulation (EU) 2020/878

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
1.11	06.04.2024	7979094-00012	Date of first issue: 19.03.2021

tative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Classification of the mixture:		Classification procedure:	
Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OE eChem Portal search results and European Chemicals Ag cy, http://echa.europa.eu/	

	olassinoation proced		
Eye Irrit. 2	H319	Calculation method	
Repr. 1B	H360FD	Calculation method	

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN